BR112019011932A2 - derivados de bis-heteroarila como moduladores da agregação de proteína - Google Patents
derivados de bis-heteroarila como moduladores da agregação de proteína Download PDFInfo
- Publication number
- BR112019011932A2 BR112019011932A2 BR112019011932-9A BR112019011932A BR112019011932A2 BR 112019011932 A2 BR112019011932 A2 BR 112019011932A2 BR 112019011932 A BR112019011932 A BR 112019011932A BR 112019011932 A2 BR112019011932 A2 BR 112019011932A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- protein aggregation
- bisheteroaryl
- methods
- modulators
- Prior art date
Links
- 230000004845 protein aggregation Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a certos compostos de bis-heteroarila, composições farmacêuticas que os contenham, e métodos de usá-los, incluindo métodos para prevenir, reverter, retardar, ou inibir a agregação de proteína, e métodos de tratar doenças que estão associadas com a agregação de proteína, incluindo doenças neurodegenerativas tais como doença de parkinson, doença de alzheimer, doença de corpo de lewy, doença de parkinson com demência, demência fronto-temporal, doença de huntington, esclerose lateral amiotrófica, e atrofia de sistema múltiplo, e câncer incluindo melanoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17153214 | 2017-01-26 | ||
| PCT/EP2018/051580 WO2018138086A1 (en) | 2017-01-26 | 2018-01-23 | Bis-heteroaryl derivatives as modulators of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019011932A2 true BR112019011932A2 (pt) | 2019-10-29 |
Family
ID=57906527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019011932-9A BR112019011932A2 (pt) | 2017-01-26 | 2018-01-23 | derivados de bis-heteroarila como moduladores da agregação de proteína |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10913735B2 (pt) |
| EP (1) | EP3573982B1 (pt) |
| JP (1) | JP7100043B2 (pt) |
| KR (1) | KR20190111080A (pt) |
| CN (1) | CN110198938B (pt) |
| AU (1) | AU2018212436A1 (pt) |
| BR (1) | BR112019011932A2 (pt) |
| CA (1) | CA3048947A1 (pt) |
| CL (1) | CL2019001752A1 (pt) |
| CO (1) | CO2019007835A2 (pt) |
| EA (1) | EA201991756A1 (pt) |
| ES (1) | ES2882285T3 (pt) |
| IL (1) | IL267994A (pt) |
| MA (1) | MA47370A (pt) |
| MX (1) | MX2019007053A (pt) |
| RU (1) | RU2019126170A (pt) |
| WO (1) | WO2018138086A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3099684T3 (en) | 2014-01-29 | 2018-07-16 | Ucb Biopharma Sprl | HETEROARYLAMIDS AS INHIBITORS OF PROTEIN AGGREGATION |
| US10975066B2 (en) | 2015-07-29 | 2021-04-13 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| CN110191885B (zh) | 2017-01-26 | 2023-05-16 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物 |
| ES2882285T3 (es) * | 2017-01-26 | 2021-12-01 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
| MX2019008256A (es) | 2017-01-26 | 2019-09-09 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| CN109053693B (zh) * | 2018-09-20 | 2021-02-05 | 顺毅股份有限公司 | 哒嗪胺类化合物的制备及其应用 |
| WO2023125376A1 (zh) * | 2021-12-27 | 2023-07-06 | 上海京新生物医药有限公司 | 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| MX335989B (es) | 2009-12-16 | 2016-01-07 | Neuropore Therapies Inc | Compuesto adecuado para el tratamiento de sinucleopatias. |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| WO2013134371A1 (en) | 2012-03-06 | 2013-09-12 | Neuropore Therapies, Inc. | Methods and compounds to be used in the treatment of neurodegenerative diseases |
| AU2013240219A1 (en) | 2012-03-28 | 2014-10-09 | Neuropore Therapies, Inc. | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
| CN104703604A (zh) | 2012-07-16 | 2015-06-10 | 神经孔疗法股份有限公司 | 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物 |
| DK3099684T3 (en) | 2014-01-29 | 2018-07-16 | Ucb Biopharma Sprl | HETEROARYLAMIDS AS INHIBITORS OF PROTEIN AGGREGATION |
| US10975066B2 (en) | 2015-07-29 | 2021-04-13 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| CN110191885B (zh) | 2017-01-26 | 2023-05-16 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物 |
| ES2882285T3 (es) * | 2017-01-26 | 2021-12-01 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
| MX2019008256A (es) | 2017-01-26 | 2019-09-09 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. |
-
2018
- 2018-01-23 ES ES18703236T patent/ES2882285T3/es active Active
- 2018-01-23 CA CA3048947A patent/CA3048947A1/en active Pending
- 2018-01-23 RU RU2019126170A patent/RU2019126170A/ru not_active Application Discontinuation
- 2018-01-23 KR KR1020197024619A patent/KR20190111080A/ko not_active Application Discontinuation
- 2018-01-23 US US16/480,252 patent/US10913735B2/en active Active
- 2018-01-23 BR BR112019011932-9A patent/BR112019011932A2/pt not_active Application Discontinuation
- 2018-01-23 AU AU2018212436A patent/AU2018212436A1/en not_active Abandoned
- 2018-01-23 MA MA047370A patent/MA47370A/fr unknown
- 2018-01-23 JP JP2019539746A patent/JP7100043B2/ja active Active
- 2018-01-23 CN CN201880007816.3A patent/CN110198938B/zh active Active
- 2018-01-23 WO PCT/EP2018/051580 patent/WO2018138086A1/en unknown
- 2018-01-23 MX MX2019007053A patent/MX2019007053A/es unknown
- 2018-01-23 EP EP18703236.2A patent/EP3573982B1/en active Active
- 2018-01-23 EA EA201991756A patent/EA201991756A1/ru unknown
-
2019
- 2019-06-21 CL CL2019001752A patent/CL2019001752A1/es unknown
- 2019-07-11 IL IL267994A patent/IL267994A/en unknown
- 2019-07-22 CO CONC2019/0007835A patent/CO2019007835A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190111080A (ko) | 2019-10-01 |
| US10913735B2 (en) | 2021-02-09 |
| MX2019007053A (es) | 2019-08-29 |
| EP3573982B1 (en) | 2021-06-16 |
| JP7100043B2 (ja) | 2022-07-12 |
| CL2019001752A1 (es) | 2019-11-22 |
| MA47370A (fr) | 2021-03-24 |
| RU2019126170A (ru) | 2021-02-26 |
| CA3048947A1 (en) | 2018-08-02 |
| EP3573982A1 (en) | 2019-12-04 |
| CN110198938B (zh) | 2023-03-14 |
| EA201991756A1 (ru) | 2020-01-23 |
| JP2020505372A (ja) | 2020-02-20 |
| US20190367502A1 (en) | 2019-12-05 |
| AU2018212436A1 (en) | 2019-07-25 |
| CN110198938A (zh) | 2019-09-03 |
| ES2882285T3 (es) | 2021-12-01 |
| CO2019007835A2 (es) | 2019-07-31 |
| WO2018138086A1 (en) | 2018-08-02 |
| IL267994A (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019011932A2 (pt) | derivados de bis-heteroarila como moduladores da agregação de proteína | |
| BR112016017344A2 (pt) | Amidas de heteroaril como inibidores de agregação de proteínas | |
| MX2019008256A (es) | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| MX2018000465A (es) | Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa. | |
| PH12015502028A1 (en) | Ido inhibitors | |
| BR112016028255A2 (pt) | agentes imunorreguladores | |
| MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| BR112015001096A2 (pt) | derivados de di e tri-heteroaril como inibidores de agregação de proteína | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| BR112016022575A2 (pt) | Composições e métodos para o tratamento de doenças neurodegenerativas | |
| BR112018073219A2 (pt) | Composto de fórmula i, composição farmacêutica, processo para síntese destescompostos e uso dos mesmos | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| MX2019007054A (es) | Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas. | |
| BR112019023130A2 (pt) | Compostos e métodos para tratamento de infecções bacterianas | |
| SG11201906819VA (en) | Ethane-sulfonate salt of quinoline derivative | |
| BR112017020180A2 (pt) | derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer | |
| BR112019027387A8 (pt) | Composições imunogênicas | |
| BR112016022439A2 (pt) | Composições farmacêuticas que compreendem cefepima ou sulbactama | |
| BR112016024236A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| BR112016030599A8 (pt) | novos derivados de aminoalquilbenzotiazepina e suas utilizações | |
| BR112017008568A2 (pt) | agentes imunorregulatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |